Stay updated with breaking news from Aduhelm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Confirmatory trial's completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of diverse
WESTON (dpa-AFX) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug Administration
A drug to prevent preterm birth may provide the next test of the agency’s process for speedily getting drugs on the market, despite limited evidence that some work.
WASHINGTON (AP) — When patients are battling a terminal illness and want access to an...
Aduhelm maker Biogen has set up a data network to track how neurological disease medicines perform in the real world after clinical trials.